Literature DB >> 16672152

Development of microalbuminuria in essential hypertension.

Josep Redon1, Jose M Pascual.   

Abstract

During the past few years, microalbuminuria has become a prognostic marker for cardiovascular and/or renal risk in diabetic and nondiabetic subjects. In essential hypertensives, an increased transglomerular passage of albumin may result from several mechanisms--hyperfiltration, glomerular basal membrane abnormalities, endothelial dysfunction, and nephrosclerosis. Cross-sectional studies have demonstrated that the main factors related to microalbuminuria are blood pressure (BP) values and hyperinsulinemia, as an expression of insulin resistance. Genetics, obesity, and smoking, however, have also been implicated as determinants of microalbuminuria in some of the studies. Follow-up studies support the role of BP values and subtle alterations in glucose metabolism, although contributing roles need to be assessed in further studies. It seems that the significance of microalbuminuria in essential hypertension is much broader than expected, and several factors may influence the presence of microalbuminuria. Thus, to reverse microalbuminuria, and to reduce urine albumin excretion and cardiovascular and renal risk, a strategy of multiple approaches may be needed. Whether or not the multiple approaches need to be implemented from the beginning or step by step in an individual approach should be established in the near future.

Entities:  

Mesh:

Year:  2006        PMID: 16672152     DOI: 10.1007/s11906-006-0015-x

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  65 in total

1.  Micro-albuminuria as a predictor of cardiovascular damage in essential hypertension.

Authors:  G Cerasola; S Cottone; G D'Ignoto; L Grasso; M T Mangano; E Carapelle; E Nardi; G Andronico; M A Fulantelli; T Marcellino
Journal:  J Hypertens Suppl       Date:  1989-12

2.  Hyperfiltration in lean essential hypertension.

Authors:  A Mimran; J Ribstein; G DuCailar; J M Halimi
Journal:  Contrib Nephrol       Date:  1996       Impact factor: 1.580

3.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

4.  Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension.

Authors:  J Redon; A Miralles; J M Pascual; E Baldó; R G Robles; R Carmena
Journal:  J Hypertens       Date:  1997-01       Impact factor: 4.844

Review 5.  Microalbuminuria in essential hypertension.

Authors:  S Ljungman
Journal:  Am J Hypertens       Date:  1990-12       Impact factor: 2.689

6.  Frequency and determinants of microalbuminuria in mild hypertension: a primary-care-based study.

Authors:  M A Martínez; A Moreno; A Aguirre de Cárcer; R Cabrera; R Rocha; A Torre; A Nevado; T Ramos; J Neri; G Antón; I Miranda; P Fernández; E Rodríguez; A Miquel; J L Martínez; M Rodríguez; C Eisman; J G Puig
Journal:  J Hypertens       Date:  2001-02       Impact factor: 4.844

Review 7.  Renal protection by antihypertensive drugs: insights from microalbuminuria studies.

Authors:  J Redon
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

8.  Sodium-lithium countertransport and cardiorenal abnormalities in essential hypertension.

Authors:  R Nosadini; A Semplicini; P Fioretto; L Lusiani; R Trevisan; V Donadon; G Zanette; G L Nicolosi; V Dall'Aglio; D Zanuttini
Journal:  Hypertension       Date:  1991-08       Impact factor: 10.190

9.  Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria.

Authors:  M R Weir; D R Dengel; M T Behrens; A P Goldberg
Journal:  Hypertension       Date:  1995-06       Impact factor: 10.190

10.  Microalbuminuria and all-cause mortality in treated hypertensive individuals: does sex matter? The Nord-Trøndelag Health Study (HUNT), Norway.

Authors:  Solfrid Romundstad; Jostein Holmen; Hans Hallan; Kurt Kvenild; Hanne Ellekjaer
Journal:  Circulation       Date:  2003-11-17       Impact factor: 29.690

View more
  7 in total

1.  N-Acetyl-β-D-Glucosaminidase Does Not Enhance Prediction of Cardiovascular or All-Cause Mortality by Albuminuria in a Low-Risk Population.

Authors:  Marit D Solbu; Ingrid Toft; Maja-Lisa Løchen; Ellisiv B Mathiesen; Bjørn O Eriksen; Toralf Melsom; Inger Njølstad; Tom Wilsgaard; Trond G Jenssen
Journal:  J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 10.121

2.  Comparison between the effects of hydrochlorothiazide and indapamide on the kidney in hypertensive patients inadequately controlled with losartan.

Authors:  S Wang; J Li; X Zhou; K Liu; X Zhang; Q Meng; R Shi; D Shi; X Chen
Journal:  J Hum Hypertens       Date:  2017-07-13       Impact factor: 3.012

3.  Incidence of microalbuminuria in hypertensive patients.

Authors:  Ravjit Kaur Sabharwal; Parduman Singh; M M Arora; B L Somani; Vivek Ambade
Journal:  Indian J Clin Biochem       Date:  2008-03-06

Review 4.  Microalbuminuria as surrogate endpoint in therapeutic trials.

Authors:  Josep Redon; Fernando Martinez
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

5.  Urine albumin excretion, within normal range, reflects increasing prevalence of metabolic syndrome in patients with essential hypertension.

Authors:  Gregory Vyssoulis; Eva Karpanou; Pangiotis Spanos; Stella-Maria Kyvelou; Dionysios Adamopoulos; Christodoulos Stefanadis
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-08       Impact factor: 3.738

6.  Clinical and pathological analysis of the kidney in patients with hypertensive nephropathy.

Authors:  Xiang-Chuan Wang; Chun-Hui Liu; Yun-Jing Chen; Yang Wu; Lei-Shan Yang; Hong-Min Liu; Hai-Li Liao
Journal:  Exp Ther Med       Date:  2013-09-18       Impact factor: 2.447

7.  Genomic and metabolomic profile associated to microalbuminuria.

Authors:  Vannina G Marrachelli; Daniel Monleon; Pilar Rentero; María L Mansego; Jose Manuel Morales; Inma Galan; Remedios Segura; Fernando Martinez; Juan Carlos Martin-Escudero; Laisa Briongos; Pablo Marin; Gloria Lliso; Felipe Javier Chaves; Josep Redon
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.